Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr
This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.
bioRxiv · Nov 22, 2021Immunology